Navigation Links
Generex Provides Update on Spinout of Antigen Express
Date:9/15/2011

e immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases.  Antigen Express has pioneered the use of specific CD4+ T helper stimulation in immunotherapy.  One of its platform technologies relies on inhibition of expression of the Ii protein.  Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T helper cells and prevents the further growth of cancer cells.  For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts.  Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not.  Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
2. Generex Announces That Adjournment will be Sole Matter Considered at Special Meeting of Stockholders on September 17, 2010
3. Generex Biotechnology Appoints Mark Fletcher as Interim President and CEO, and John P. Barratt as Chairman of the Board
4. Generex Plans Rights Offering to Stockholders Following Reverse Stock Split
5. Generex Scientific Advisor Weighs in on Reverse Stock Split Proposal
6. Generex Provides Additional Reverse Stock Split Information for the Consideration of Stockholders
7. Generex Common Stock to be Quoted on the OTCQB Under the Symbol GNBT Beginning Thursday, October 21, 2010
8. Generex Provides Additional Details for October 21st Live Video Webcast
9. Generex Announces $3.0 Million Capital Investment
10. Generex Announces Publication of Comparative Peptide Vaccine Studies in Peer Review Journal Demonstrating Superiority of AE37 and Presentation at the American Association for Cancer Research
11. Generex Oral-lyn™ Data to be Presented at Two International Scientific Symposia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... PARK, Calif. , Aug. 28, 2014 /PRNewswire/ ... focused on developing novel mid- to late-stage cardiovascular ... $7.0 million in its first round of financing. ... Biomedical Investments and Hercules Bioventures with participation from ... entrepreneur and pharmaceutical executive, Dr. Larry Hsu ...
(Date:8/28/2014)... Vt. (PRWEB) August 28, 2014 ... testing around the world is available from Strategic ... diagnostics companies. “ Industrial Microbiology Market Review, Fourth ... Industrial Market ” (IMMR—4) tracks and compares microbiology ... in North America, Europe and Asia, and forecasts ...
(Date:8/28/2014)... 2014 Supplementing their complete line ... for Eppendorf Safe Lock Centrifuge Tubes . ... highest quality tubes at an affordable price. Eppendorf ... doing chemical, medical, pharmaceutical, and life science research ... regularly able to afford Eppendorf products. , Eppendorf ...
(Date:8/27/2014)... Green & Grow Inc. (GGI) has ... and secured Otter Capital as a significant new partner. ... of GGI’s Agriplier™ technology, building on recent compelling field ... our first meeting, we have been impressed with Otter ... said Alan Sobba, President and CEO of GGI. “We ...
Breaking Biology Technology:Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 32 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 22 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 3Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 2Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 3Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3
... Mass. and SAN DIEGO, Calif., April 16 ,Boston ... Inc. (Nasdaq: CRYO ),today announced the signing ... will pay a cash purchase price of $1.35 ... acquisition follows a,development agreement, in place since June ...
... the 99th Annual Meeting of the American ... Association for Cancer Research (AACR) ... Inc.,("Lorus") (TSX: LOR; AMEX: LRP), a biopharmaceutical company specializing,in ... for the management of cancer, today announced,presentations of further ...
... Serono and its US,affiliate EMD Serono, Inc., both ... planned expansion of EMD Serono,s US presence with ... facility northwest,of Boston, Massachusetts. The company anticipates that ... in Massachusetts., The investment will support the ...
Cached Biology Technology:Boston Scientific and CryoCor Announce Signing of Definitive Merger Agreement 2Boston Scientific and CryoCor Announce Signing of Definitive Merger Agreement 3Boston Scientific and CryoCor Announce Signing of Definitive Merger Agreement 4Boston Scientific and CryoCor Announce Signing of Definitive Merger Agreement 5Boston Scientific and CryoCor Announce Signing of Definitive Merger Agreement 6Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040 2Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040 3Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040 4EMD Serono Announces Planned Investment of $50 Million in Research Center in Massachusetts 2EMD Serono Announces Planned Investment of $50 Million in Research Center in Massachusetts 3EMD Serono Announces Planned Investment of $50 Million in Research Center in Massachusetts 4
(Date:8/28/2014)... FASEB MARC (Maximizing Access to Research Careers) Program ... American College of Sports Medicine,s Conference on Integrative ... Miami, Florida. These awards are meant to ... scientists from underrepresented groups into the mainstream of ... participation of young scientists at the American College ...
(Date:8/28/2014)... measuring and imaging how quickly blood flows in the ... drug abuse affects the brain, which may aid in ... better treatment options for recovering drug addicts. The new ... Brook University in New York, USA and the U.S. ... Optical Society,s (OSA) open-access journal Biomedical Optics ...
(Date:8/28/2014)... 25 million kilometres of new roads will be built ... into Earth,s last wildernesses, where they bring an influx ... Now, an ambitious study has created a ,global roadmap, ... to balance the competing demands of development and environmental ... layer that estimates that natural importance of ecosystems and ...
Breaking Biology News(10 mins):This is your brain's blood vessels on drugs 2This is your brain's blood vessels on drugs 3Study shows where on the planet new roads should and should not go 2Study shows where on the planet new roads should and should not go 3
... Livermore National Laboratory physicist and his colleagues have found ... used in physics to help solve problems in biology. ... modeling to shed light on something known as epigenetic ... memory of some variable condition, such as quality of ...
... had been reckoned until today to be around 2,000 million ... fish, in other words, ones found at depths of between ... international team*, in which AZTI-Tecnalia researchers are participating and which ... has discovered that its abundance could be at least 10 ...
... by excessive and systemic reaction of the entire body ... The number of deaths by septic shock in intensive ... despite numerous large scale clinical trials. Scientists of VIB ... mouse study that a potential novel treatment for sepsis ...
Cached Biology News:New application of physics tools used in biology 2Researchers at UGent and VIB, discovered potential novel treatment against septic shock 2
...
cysteine and glycine-rich protein 2,...
... Antitumour agent and DNA-topoisomersae II inhibitor (IC50 = ... C 29 H 32 O 13 ... Store at: RT ... Solubility: Soluble to 100 ...
HSPBP1 Antibody...
Biology Products: